Form 4: Iteos Therapeutics Director, Jill DeSimone, Acquires Stock Options

Jill DeSimone, a director of Iteos Therapeutics, acquired 24,200 stock options on June 11, 2024, at an exercise price of $16.32.

Summary

• On June 11, 2024, Jill DeSimone, a director of Iteos Therapeutics, acquired 24,200 stock options.
• The exercise price for these options is $16.32.
• The options become exercisable on June 11, 2025, and expire on June 11, 2034.
• Following the transaction, DeSimone directly owns 24,200 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants. The director's acquisition could be seen as a slightly positive signal, but it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates